Education

Dec 04, 2025

4 Factors That Affect Your Transthyretin Amyloidosis (ATTR) Prognosis

Nov 18, 2025

Diagnosed With ATTR-CM: What Should I Do Now?

Nov 12, 2025

Amyloidosis Symptoms & Causes (Mayo Clinic)

Oct 18, 2025

Clinical Utility of AI Based Review of Echocardiography for Diagnosis of Cardiac Amyloidosis

Oct 17, 2025

AL Amyloidosis: A Real-World Experience with CAR-T Cell Therapy

AL Amyloidosis: A Real-World Experience with CAR-T Cell TherapyMelinda SY Tan1 , Rahma Warsame1 , Ricardo Parrondo2 , Eli Muchtar1 , Taxiarchis Kourelis1 , Francis…

Oct 16, 2025

Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis

Key PointsElranatamab elicits deep and rapid heme responses in patients with relapsed AL amyloidosis, including minimal residual disease negativity.No new adverse…

Sep 29, 2025

Serum and Tissue Light-Chains as Disease Biomarkers in AL Amyloidosis

Amyloid light-chain (AL) amyloidosis is the most prevalent type of diagnosed systemic amyloidosis in Western countries, characterized by the deposition of misfolded…

Sep 23, 2025

Patient Insights: Think Beyond the Silos

Aug 12, 2025

Multiple Myeloma and Amyloidosis Program

Aug 11, 2025

Transthyretin-Related Cardiac Amyloidosis: A Case of Delayed Diagnosis in the Comorbid Patient and Literature Review

1
2
3
4
5
6
7
8
9
…
Next page
Last page

Subscribe to

Newsletter

Expert and Community Perspectives on Attruby®

In this special session, Dr. Barry Trachtenberg and members of the ATTR amyloidosis community came together to share medical insights and lived experiences related to Attruby™ (acoramidis). This expert-led discussion explores the clinical data, the patient perspective, and what lies ahead for those considering or currently taking Attruby.